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ABSTRACT Filoviruses are the causative agents of an increasing number of dis-
ease outbreaks in human populations, including the current unprecedented
Ebola virus disease (EVD) outbreak in western Africa. One obstacle to controlling
these epidemics is our poor understanding of the host range of ﬁloviruses and
their natural reservoirs. Here, we investigated the role of the intracellular ﬁlovi-
rus receptor, Niemann-Pick C1 (NPC1) as a molecular determinant of Ebola virus
(EBOV) host range at the cellular level. Whereas human cells can be infected by
EBOV, a cell line derived from a Russell’s viper (Daboia russellii) (VH-2) is resistant
to infection in an NPC1-dependent manner. We found that VH-2 cells are resis-
tant to EBOV infection because the Russell’s viper NPC1 ortholog bound poorly
to the EBOV spike glycoprotein (GP). Analysis of panels of viper-human NPC1
chimeras and point mutants allowed us to identify a single amino acid residue in
NPC1, at position 503, that bidirectionally inﬂuenced both its binding to EBOV
GP and its viral receptor activity in cells. Signiﬁcantly, this single residue change
perturbed neither NPC1’s endosomal localization nor its housekeeping role in
cellular cholesterol trafﬁcking. Together with other recent work, these ﬁndings
identify sequences in NPC1 that are important for viral receptor activity by virtue
of their direct interaction with EBOV GP and suggest that they may inﬂuence ﬁ-
lovirus host range in nature. Broader surveys of NPC1 orthologs from vertebrates
may delineate additional sequence polymorphisms in this gene that control sus-
ceptibility to ﬁlovirus infection.
IMPORTANCE Identifying cellular factors that determine susceptibility to infection
can help us understand how Ebola virus is transmitted. We asked if the EBOV recep-
tor Niemann-Pick C1 (NPC1) could explain why reptiles are resistant to EBOV infec-
tion. We demonstrate that cells derived from the Russell’s viper are not susceptible
to infection because EBOV cannot bind to viper NPC1. This resistance to infection
can be mapped to a single amino acid residue in viper NPC1 that renders it unable
to bind to EBOV GP. The newly solved structure of EBOV GP bound to NPC1 con-
ﬁrms our ﬁndings, revealing that this residue dips into the GP receptor-binding
pocket and is therefore critical to the binding interface. Consequently, this otherwise
well-conserved residue in vertebrate species inﬂuences the ability of reptilian NPC1
proteins to bind to EBOV GP, thereby affecting viral host range in reptilian cells.
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Ebola virus (EBOV) is the causative agent of highly lethal zoonotic infections inhumans and nonhuman primates in sub-Saharan Africa (1–3). Despite the emerging
roles of EBOV and related members of the family Filoviridae (ﬁloviruses) in human
disease, our knowledge of the ecological host range of these agents remains limited.
Bats are thought to be important reservoirs for ﬁloviruses; however, conclusive evi-
dence in favor of this hypothesis has been obtained only for Marburg virus (MARV) and
Ravn virus (RAVV), which were recently found to circulate in Egyptian rousettes
(Rousettus aegyptiacus) (4–7).
Previous studies demonstrated that, whereas a broad range of mammalian and
avian cell lines are susceptible to EBOV and/or MARV, all tested reptilian and amphibian
lines are resistant to infection (8–10). These ﬁndings suggested the existence of one or
more unknown determinants of ﬁlovirus host range. Although the determinants of
ﬁlovirus infection and disease at the organismal level are likely to be complex, it is well
established that interactions between viruses and cell-intrinsic host factors, such as
entry receptors, can dictate host range. For example, ortholog-speciﬁc sequence vari-
ations in angiotensin-converting enzyme 2 (ACE2) and transferrin receptor (TfR1)
inﬂuence the host range of viruses for which they serve as receptors (severe acute
respiratory syndrome-related coronaviruses [11, 12] and New World mammarenavi-
ruses, canine parvoviruses, and murine mammary tumor virus [13–18], respectively). Jae
and coworkers demonstrated that chicken cells are resistant to infection by an Old
World arenavirus, Lassa virus, because of a single amino acid difference in the chicken
ortholog of its intracellular receptor, LAMP1 (19).
We and others recently demonstrated that Niemann-Pick C1 (NPC1), a large endo/
lysosomal membrane protein involved in cellular cholesterol trafﬁcking, is an essential
intracellular receptor for ﬁlovirus entry and infection (20–23). We also found that NPC1
could inﬂuence the cellular host range of ﬁloviruses—human NPC1 conferred suscep-
tibility to ﬁlovirus entry and infection when expressed in the nonpermissive reptilian
cell line VH-2, derived from a Russell’s viper (Daboia russellii) (22). In that study,
however, we did not establish the molecular basis of the NPC1-dependent block to viral
entry in VH-2 cells.
Recently, we found that a single amino acid residue (position 502) in the second
luminal domain of NPC1, domain C, is under positive selection in bats and controls the
susceptibility of bat cells to EBOV infection in a host species-dependent manner (24,
25). Here, we demonstrate that an adjacent residue, 503, highly conserved in domain
C of NPC1, inﬂuences EBOV host range in reptilian cells by controlling its activity as a
ﬁlovirus receptor. The recently solved structure of the EBOV entry glycoprotein (GP1,2;
hereafter referred to as GP) bound to domain C shows that these two residues are in
a loop that dips into the exposed receptor-binding site (26). Therefore, our ﬁndings
identify a hot spot in NPC1 at the EBOV GP-binding interface that inﬂuences virus-
receptor recognition and host cell susceptibility, suggesting evolutionary scenarios in
which antagonism with ﬁloviruses could sculpt host NPC1 genes selectively, without
compromising their ancient, and essential, function in cellular cholesterol homeostasis.
RESULTS
The second luminal domain of the Russell’s viper NPC1 ortholog binds poorly to
the Ebola virus glycoprotein. We postulated that EBOV fails to enter and infect
Russell’s viper VH-2 cells because the EBOV entry glycoprotein, GP, cannot recognize
the viper ortholog of the ﬁlovirus intracellular receptor, Niemann-Pick C1 (Daboia
russellii NPC1 [DrNPC1]). We previously showed that the second luminal domain (C) of
human NPC1 (Homo sapiens NPC1 [HsNPC1]) directly contacts a cleaved form of EBOV
GP (GPCL) and that GPCL-HsNPC1 domain C binding is essential for ﬁlovirus entry (22,
23). Accordingly, we investigated the capacity of DrNPC1 domain C to bind to GPCL and
support EBOV entry and infection.
We ﬁrst used reverse transcription-PCR (RT-PCR) to isolate and sequence DrNPC1
domain C. Alignment of domain C amino acid sequences from HsNPC1 and DrNPC1
revealed a substantial degree of conservation (80% amino acid identity), with identical
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arrangements of cysteine residues and similar predicted secondary structures, suggest-
ing a similar overall fold for the two proteins (Fig. 1).
To facilitate in vitro GPCL-NPC1-binding studies, we engineered a soluble form of
DrNPC1 domain C, as previously described for HsNPC1 (22). Transfection of HEK 293T
cells with this construct afforded the secretion of an extensively N-glycosylated form of
DrNPC1 domain C (Fig. 2A). As shown previously, puriﬁed HsNPC1 domain C could bind
to recombinant vesicular stomatitis virus Indiana particles bearing cleaved EBOV GP
(rVSV-GPCL), as measured by enzyme-linked immunosorbent assay (ELISA) (22); in
contrast, DrNPC1 domain C exhibited no binding by ELISA, even at the highest
concentration tested (Fig. 2B). Therefore, DrNPC1 domain C, in contrast to its human
counterpart, recognizes the EBOV glycoprotein poorly or not at all.
DrNPC1 domain C can substitute for HsNPC1 domain C in mediating
endo/lysosomal cholesterol clearance but not EBOV entry and infection. While
the efﬁcient secretion of the soluble, glycosylated DrNPC1 domain C construct sug-
gested that it was not misfolded, it was nevertheless conceivable that subtle structural
aberrations rendered this protein biologically inactive. Accordingly, we assessed the
capacity of DrNPC1 domain C to support NPC1’s best-established cellular function—
clearance of unesteriﬁed cholesterol from endo/lysosomal compartments (Fig. 3A and B).
This activity requires the full-length NPC1 protein, including all three major luminal
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FIG 1 Alignment of human and viper NPC1 domains C. (A) Schematic of full-length NPC1 protein, showing luminal domains A, C, and I. (B) Alignment
of NPC1 domain C sequences from human and Russell’s viper. Cysteine residues are in blue. Predicted N-glycosylation sites (sequons) that are conserved
in the two proteins are indicated with black arrowheads. Orange arrowheads mark those unique to Russell’s viper NPC1 domain C, and a green arrowhead
marks one that is unique to human NPC1 domain C. Nonidentical residues are highlighted in yellow. Position 503 is highlighted in pink.
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FIG 2 Both HsNPC1 and DrNPC1 domain C proteins are expressed and secreted but bind differen-
tially to EBOV GPCL. (A) Soluble forms of the NPC1 domain C proteins from human (HsNPC1) and
Russell’s viper (DrNPC1) were expressed in FreeStyle 293-F cells and purified by nickel-affinity
chromatography. Equal concentrations were resolved by anti-Flag immunostaining. Left, no treat-
ment. Right, treatment with protein N-glycosidase F (PNGase F). Numbers at left are molecular
masses in kilodaltons, and numbers at right are relative molecular weights in thousands. (B) The two
NPC1 domain C proteins were tested in an ELISA for binding to EBOV GPCL. VSV-EBOV GP viruses were
cleaved with thermolysin (250 g/ml) and captured on an ELISA plate using monoclonal antibody
KZ52. Serial dilutions of either HsNPC1 or DrNPC1 domain C proteins were added, and binding to
GPCL was detected by anti-Flag antibody.
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domains, A, C, and I. We therefore generated and tested an HsNPC1 chimera in which
domain C (residues 373 to 620) was seamlessly replaced with its viper counterpart
(HsNPC1-DrC)—we previously found that replacing domain C in NPC1 using restriction
site cloning, which introduced two additional amino acid residues at each junction,
resulted in proteins that were defective in localization and cholesterol clearance. The
wild-type (WT) HsNPC1 and HsNPC1-DrC chimera constructs were then stably expressed
in the NPC1-null Chinese hamster ovary (CHO) M12 cell line (24). As expected, immu-
nostaining of WT HsNPC1 transiently expressed in a U2OS NPC1/ cell line (27)
showed colocalization with the endo/lysosomal marker LAMP1 (Fig. 3A) The behavior
of HsNPC1-DrC resembled that of WT HsNPC1, indicating that it too localizes to
endo/lysosomal compartments (Fig. 3A). These results suggest that DrNPC1 domain C
is correctly folded and does not interfere with the correct folding and trafﬁcking of
full-length HsNPC1.
We next monitored the cholesterol clearance activity of each protein upon stable
expression in NPC1-null M12 cells (Fig. 3B). Filipin, a ﬂuorescent probe for free choles-
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FIG 3 HsNPC1-DrC chimera is functional at cholesterol clearance from lysosomes but does not support EBOV entry and infection. (A)
Full-length NPC1 constructs—human WT (HsNPC1) and the human NPC1 chimera with the domain C replaced with viper domain C
(HsNPC1-DrC)—immunostained with anti-Flag antibody (red) colocalize with the lysosomal marker LAMP1 (green) when transiently
expressed in U2OS NPC1/ cells (27). (B) CHO-M12 cells stably expressing either HsNPC1 WT or HsNPC1-DrC were stained with filipin to
visualize unesterified cholesterol. Top panel, filipin staining. Cholesterol-laden cells are marked with red arrowheads. Blue arrowheads
indicate cells that are functional at cholesterol clearance. Bottom panel, cells immunostained with anti-Flag antibody for NPC1 expression
(green). (C) Infection of cells from panel B by authentic EBOV (multiplicity of infection of 10), scored 72 h postinfection and normalized to
infection on HsNPC1(WT). (D) Infection of cells from panel B by VSV-EBOV GP calculated by manual counting of eGFP-positive cells. IU/ml,
infectious units per milliliter. Means  standard deviations (n  2 to 4) from a representative experiment are shown in each panel.
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terol, extensively stained the cholesterol-laden endo/lysosomal compartments of the
parental M12 cells, as shown previously (24). Ectopic HsNPC1 expression could clear this
accumulated cholesterol, as previously described (20), substantially reducing ﬁlipin
staining. Remarkably, HsNPC1-DrC could rescue cholesterol clearance as efﬁciently as
WT HsNPC1 (Fig. 3B). These ﬁndings afﬁrm that DrNPC1 domain C is biologically active
and competent to perform a major housekeeping function of its human counterpart,
despite its divergence from the latter at 48 out of 248 amino acid positions (Fig. 1).
Finally, we challenged M12 cell lines expressing WT HsNPC1 or HsNPC1-DrC with
authentic EBOV (Fig. 3C). Replacement of human domain C with its Russell’s viper
ortholog reduced EBOV infection by almost 3 orders of magnitude. Similar results were
obtained in infections with rVSV-EBOV GP (Fig. 3D), conﬁrming that the DrNPC1 domain
C-imposed infection block occurs at the viral entry step. Taken together, these obser-
vations afford two conclusions. First, the failure of DrNPC1 to support EBOV entry and
infection arises at least in part because its domain C cannot bind to EBOV GPCL. Second,
one or more differences between the domain C sequences of HsNPC1 and DrNPC1
render DrNPC1 bereft of viral receptor activity without perturbing its normal function
in cellular cholesterol homeostasis.
Differences in N-glycosylation do not explain the defect in EBOV GPCL-
DrNPC1 domain C binding. To uncover the molecular basis of DrNPC1’s defective
viral receptor function, we engineered and tested a panel of mutant, soluble NPC1
domain C constructs in both HsNPC1 and DrNPC1 backgrounds. We ﬁrst considered the
possibility that one or more differences in N-linked glycosylation sites determine the
HsNPC1-DrNPC1 difference, because it is either required for GPCL-HsNPC1 binding or
deleterious for GPCL-DrNPC1 binding (Fig. 4). Six sequons are conserved between the
two proteins, but DrNPC1 and HsNPC1 domains C contain two and one unique sequons,
respectively. Accordingly, we generated soluble domain C proteins containing or
lacking each unique sequon and tested these putative gain-of-function and loss-of-
function mutants for binding to EBOV GPCL. “Humanized” DrNPC1 domain C proteins
engineered to lack their unique sequons at position 414 or 498 (HsNPC1 numbering) or
to gain the sequon at position 598 remained defective at EBOV GPCL binding in the
ELISA. Conversely, HsNPC1 domain C proteins engineered to resemble DrNPC1 at each
of these three positions remained fully competent to bind to EBOV GPCL. Therefore,
WT
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N414A
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R600T
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FIG 4 N-glycosylation of NPC1 domain C does not affect EBOV GPCL binding. (A) Location of the
three unique sequons in HsNPC1 versus DrNPC1 domain C. (B) Glycosylation mutants were made in
both HsNPC1 (losing sequon at position 598 and gaining sequons at position 414 and 498) and
DrNPC1 (losing sequons at position 414 and 498 and gaining sequon at position 598). Domain C
proteins were expressed in HEK 293T cells and tested for EBOV GPCL binding by ELISA.
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differences in N-linked glycosylation between the domains C of HsNPC1 and DrNPC1 do
not account for the defective EBOV receptor activity of DrNPC1.
A single point mutation renders DrNPC1 domain C competent to bind to
EBOV GPCL. Having ruled out a role for variations in N-glycosylation, we next adopted
a systematic approach to identify determinative sequences in NPC1 domain C. We
expressed a series of soluble HsNPC1-DrNPC1 domain C chimeras and measured their
activity in the GPCL-binding ELISA (Fig. 5). However, only chimera 2, DrNPC1 domain C
containing HsNPC1 residues 476 to 536, afforded GPCL-NPC1 binding (Fig. 5A).
Chimera 2 introduced 14 Russell’s viper¡human amino acid changes into DrNPC1.
To further dissect their roles, we generated and tested three additional chimeras
containing subsets of these amino acid changes (chimeras 4 to 6, Fig. 5B) in the
GPCL-binding ELISA. The subregion chimera 5 fully reconstituted GPCL-DrNPC1 domain
C binding, providing evidence that one or more of the 6 HsNPC1 residues in this
construct confer gain of function on DrNPC1.
To assess the individual contributions of the six Russell’s viper¡human amino acid
changes in chimera 5, we separately introduced these changes into soluble DrNPC1
domain C and tested the capacity of each point mutant to bind to EBOV GPCL (Fig. 6).
A single conservative mutation, Y503¡F, fully restored GPCL-DrNPC1 domain C binding,
whereas the other 5 mutations had no discernible effect. Thus, the presence of Y
instead of F at position 503 appears to completely explain the failure of DrNPC1 to bind
to EBOV GPCL.
F↔Y sequence change at residue 503 controls NPC1’s function as an EBOV
entry receptor without affecting its housekeeping function. We postulated that
the F↔Y sequence change at residue 503 might inﬂuence EBOV GPCL-NPC1 binding in
a bidirectional manner. Accordingly, we expressed and puriﬁed the reciprocal
DrNPC1(Y503F) and HsNPC1(F503Y) domain C mutants and tested them in the GPCL-
binding ELISA (Fig. 7). Puriﬁed DrNPC1(Y503F) domain C bound almost as well as its
human counterpart to EBOV GPCL (50% effective concentration [EC50] for binding,
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FIG 5 Middle region of HsNPC1 domain C confers binding ability on DrNPC1. (A) Chimeras were engineered
by replacing DrNPC1 domain C sequences with human sequence 373 to 475 (chimera 1), 476 to 536 (chimera
2), or 537 to 620 (chimera 3). The chimeras were expressed in HEK 293T cells and tested for EBOV GPCL binding
by ELISA. (B) Further dissection of chimera 2 was done by replacing smaller subsets of DrNPC1 with human
residues 494 to 502 (chimera 4), 502 to 511 (chimera 5), and 527 to 531 (chimera 6). Chimeric NPC1 domain
C proteins were tested as in panel A.
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3 nM [Russell’s viper] versus 0.5 nM [human]). Conversely, no detectable GPCL binding
was obtained with the HsNPC1(F503Y) domain C protein (EC50, 1 M).
To examine the consequences of the 503(F↔Y) sequence change for the cellular
and viral receptor functions of NPC1, we introduced the F503Y and Y503F mutations
into full-length WT HsNPC1 and the HsNPC1-DrC chimera, respectively, and expressed
them transiently in U2OS NPC1/ cell lines. Immunostaining of NPC1 in these cell lines
revealed colocalization with LAMP1 for both WT HsNPC1 and HsNPC1-DrC (Fig. 8A and
3A). Furthermore, ﬁlipin staining showed little or no cholesterol accumulation in
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FIG 6 A single amino acid change renders DrNPC1 domain C fully competent to bind EBOV GPCL.
Chimera 5 contains 6 amino acid differences between DrNPC1 and HsNPC1 domain C. The following
point mutations were made in the DrNPC1 domain C by switching the viper amino acid residue at
each of these positions to the corresponding human residue: E502D, Y503F, I505V, H506Y, F509Y,
and S511T. The point mutants were expressed in HEK 293T cells and tested for EBOV GPCL binding
by ELISA.
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FIG 7 NPC1 residue 503 bidirectionally alters domain C’s capacity to bind EBOV GPCL. (A) HsNPC1
and DrNPC1 domain C proteins bearing point mutations at residue 503 (HsNPC1, F503Y; DrNPC1,
Y503F) were expressed and purified. (B) Serial dilutions of equivalent amounts of purified NPC1
domain C proteins were tested for EBOV GPCL binding by ELISA.
Ebola Virus Host Range Determinants in Reptiles
Volume 1 Issue 2 e00007-16 msphere.asm.org 7
BDC
Filipin
Filipin+
NPC1
20 µm
A
HsNPC1
(F503Y)
HsNPC1–
DrC(Y503F)
HsNPC1(F503Y) HsNPC1–DrC(Y503F)
NPC1:
WT
F503Y
WTHsNPC1
–DrC Y503F
HsNPC1
HsNPC1
–DrC
NPC1:
WT
F503Y
WT
Y503F
HsNPC1
1 10 1000.1 5 6 7 8
5 µm
LAMP1
LAMP1
NPC1
LAMP1
LAMP1
NPC1 NPC1
NPC1
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microscopy. (B) NPC1-deficient CHO-M12 cells stably expressing either HsNPC1 (F503Y) or HsNPC1-DrC (Y503F) were stained with
filipin to visualize unesterified cholesterol. Top panel, filipin staining. Bottom panel, cells immunostained with anti-Flag antibody for
NPC1 expression (green). Cholesterol-laden cells are marked with red arrowheads. Blue arrowheads indicate cells that are functional
at cholesterol clearance. (C) CHO-M12 cells stably expressing the NPC1 proteins indicated were exposed to authentic virus (multiplicity
of infection of 3), scored at 72 h postinfection, and normalized to HsNPC1 WT infectivity. (D) Infection by VSV-EBOV GP, calculated by
manual counting of eGFP-positive cells. IU/ml, infectious units per milliliter. Means  standard deviations (n  4) from a represen-
tative experiment are shown in each panel.
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CHO-M12 cells stably expressing HsNPC1(F503Y) or HsNPC1-DrC(Y503F) (Fig. 8B). There-
fore, the F503Y and Y503F mutations do not substantially affect the folding, endosomal
delivery, and cholesterol clearance function of NPC1.
Finally, we challenged cell lines expressing the 503(F↔Y) NPC1 mutants with
authentic EBOV and rVSV-EBOV GP (Fig. 8C). The capacities of both authentic and
surrogate viruses to enter and infect these cells were fully congruent with the results
of the GP-binding experiments. The viper¡human Y503F mutation afforded the com-
plete restoration of viral infection in cells expressing the HsNPC1-DrC chimera (3 log10
unit increase). Reciprocally, the human¡viper F503Y mutation reduced viral infection
in cells expressing HsNPC1 by2 log10 units. Thus, the infection data correlate with the
GPCL-domain C-binding data, demonstrating that switching the residue at position 503
changes the ability of human and Russell’s viper NPC1 domain C to bind EBOV GPCL,
thereby determining the ability of these NPC1 proteins to be used as EBOV receptors.
A bulky, hydrophobic amino acid residue at position 503 favors EBOV
GPCL-NPC1 domain C binding. To determine the mechanism by which the change
in NPC1 residue 503 controls binding of HsNPC1 to EBOV GPCL, we engineered a series
of NPC1 domain C proteins bearing amino acid residues with divergent physicochem-
ical properties at position 503. Examination of these mutants by GPCL-binding ELISA
revealed that binding avidity was generally correlated with amino acid size and polarity
(Fig. 9A). Speciﬁcally, residues with bulky, hydrophobic side chains (L and W) afforded
GPCL-NPC1 binding at WT levels, whereas residues with polar side chains (D, H, and S)
abrogated binding. Binding was greatly reduced, but detectable, with A and T at
residue 503. The recently solved structure of EBOV GPCL bound to NPC1 domain C
shows that residue 503 inserts into the hydrophobic trough of EBOV GPCL (28, 29),
similarly to residue F225 of the EBOV glycan cap (Fig. 9B and C) (26).
The tyrosine residue at position 503 controls EBOV GPCL-binding function
in reptile NPC1 domain C orthologs. Finally, we asked if our ﬁndings had implica-
tions for host cell range in other vertebrates, especially reptiles, which appear to be
refractory to infection by EBOV (8, 30). An alignment of available NPC1 domain C
sequences from a panel of vertebrate species revealed that, although there exist a
number of differences in amino acid sequence around residue 503, the F at this position
is itself very well conserved among vertebrates, with only two NPC1 orthologs—those
of the Russell’s viper and king cobra (Ophiophagus hannah)—encoding a Y at this
position (Fig. 10A). Interestingly, the predicted NPC1 polypeptide sequences of two
additional snakes, the Burmese python (Python bivittatus) and the common garter
snake (Thamnophis sirtalis), show an F at position 503 (Fig. 10A). To investigate the
GPCL-binding capacities of the snake NPC1 orthologs, we expressed and puriﬁed
soluble NPC1 domain C proteins for the king cobra and Burmese python and tested
them for binding to EBOV GPCL. The capacity of these proteins to bind to EBOV GPCL
was concordant with the identity of the residue at NPC1 codon 503. Thus, king cobra
NPC1 domain C(Y503) resembled viper NPC1 domain C in its inability to bind to EBOV
GPCL, whereas Burmese python NPC1 domain C(F503) readily bound to EBOV GPCL
(Fig. 10B). We tested two more reptilian NPC1 orthologs—from Chinese softshell turtle
and Carolina anole (both carrying F503)—and found that they could all bind to EBOV
GPCL (Fig. 10C). These ﬁndings provide additional evidence that NPC1-encoded residue
503 inﬂuences the cellular host range of EBOV at the level of virus-receptor recognition
and raise the possibility that sequence differences at this position inﬂuence the
susceptibility of reptiles to ﬁlovirus infection in nature.
DISCUSSION
The essential entry receptor NPC1 is the ﬁrst known molecular determinant of the
cellular host range of EBOV and other ﬁloviruses (25, 26). In this study, we uncover one
mechanism by which NPC1 imposes a species-speciﬁc barrier to EBOV infection. We
show that reptilian cells derived from the Russell’s viper, Daboia russellii, are largely
resistant to EBOV entry and infection because of the presence of a Y residue at position
503 in NPC1, whereas the NPC1 orthologs of most other types of animals, include
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humans, carry a highly conserved F residue. Unexpectedly, toggling this residue
between F and Y in either human or Russell’s viper NPC1 backgrounds switched each
protein’s ability to act as an EBOV receptor. NPC1’s crucial housekeeping function—
distribution of cholesterol from the endo/lysosomal compartment to other cellular
membranes—remained unaffected by these changes. Thus, our work identiﬁes a
genetic determinant in NPC1 that controls its viral receptor function, and consequently
host susceptibility to EBOV infection, in a manner that is selective and yet transferable
between highly divergent NPC1 orthologs.
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The determinative F503¡Y change is located in NPC1’s second luminal domain (C),
which directly binds to a cleaved form of the EBOV entry glycoprotein (GPCL) during
viral entry (22, 23, 26). Here, we found that F503¡Y renders cells nonpermissive to
EBOV infection because it reduces the apparent binding afﬁnity of GPCL for NPC1
domain C by more than 1,000-fold. What mechanism might account for this extraor-
dinary effect of a single hydroxyl group on virus-receptor interaction?
The recently solved structure of the EBOV GPCL bound to NPC1 domain C reveals
that F503 in human NPC1 domain C inserts deeply into the hydrophobic GPCL trough
during GP-NPC1 interaction, in a manner that resembles the interaction of F225 in the
GP glycan cap with the GPCL trough in uncleaved GP (Fig. 9B and C) (26). The
introduction, at position 503, of a polar hydroxyl group (Y) or other polar side chains (D,
H, S, and G) is likely to be energetically unfavorable, thereby reducing the afﬁnity of
GPCL-NPC1 binding.
We recently demonstrated that residue 502 in NPC1 was under positive selection in
bats and was responsible for the reduced susceptibility of African straw-colored fruit
bat cells to EBOV infection (25, 31). Since none of the bat species genes encodes a Y at
position 503 in NPC1, there was no observed signature of positive selection at this
residue. The structure rationalizes the effect of these residues on GP-NPC1 binding, as
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both are located in the 4-5 loop of NPC1 domain C that directly interacts with EBOV
GPCL (“loop 2” [26]) (Fig. 9C).
It is unclear what relationships, if any, exist (or have existed) in nature between
ﬁloviruses and snakes or other reptiles. Experimental infections of wild-caught reptiles
and amphibians by Swanepoel and colleagues (30) showed a general refractoriness to
EBOV infection or replication, but minimal titers were recovered on a few occasions
from the brown house snake (Lamprophis fuliginosus). Following outbreaks of the Ebola
virus relative Marburg virus (MARV) at the mine in Kitaka Cave, the nearby “Python
Cave” in Queen Elizabeth National Park in Uganda (32, 33), and the Goroumbwa Mine
in the Democratic Republic of the Congo (31), a number of Egyptian fruit bats were
found to be infected with MARV (5, 6, 24, 34). Unfortunately, though the African rock
python (Python sebae) and forest cobra (Naja Melanoleuca) are part of the fauna in these
locations, there were no reports on investigations of snakes from these caves for
ﬁlovirus infection (6, 22, 31). Nevertheless, our ﬁnding that two snake NPC1 orthologs
are nonpermissive to ﬁlovirus entry and infection due to a single amino acid change
leads us to speculate that this change was an adaptation to reduce infection by a
ﬁlovirus, thereby increasing host survivability. More-extensive wildlife sampling cou-
pled with genetic and functional analysis of host-virus interactions associated with
ﬁlovirus infection may uncover additional evidence for evolutionary arms races be-
tween ﬁloviruses and multiple types of animals (bats, reptiles, and rodents).
MATERIALS AND METHODS
Cells. Vero grivet HEK 293T and U2OS cells were maintained in high-glucose Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Thermo Fisher Scientiﬁc, Waltham MA) supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin-streptomycin (Thermo Fisher Scientiﬁc)
at 37°C and 5% CO2. U2OS NPC1/ cell lines were generated by CRISPR/Cas9 genome editing as
previously described (27) and transiently transfected with NPC1 constructs for colocalization experi-
ments. Chinese hamster ovary (CHO) cells were maintained in DMEM–Ham’s F-12 medium (50/50 mix)
(Thermo Fisher Scientiﬁc) supplemented with 10% FBS at 37°C and 5% CO2. Cell lines were generated by
a retroviral transduction system, as previously described (22), to stably overexpress the NPC1 constructs
in CHO-M12 cells, which contain a deletion in the NPC1 locus (24). FreeStyle 293-F cells were maintained
in Gibco FreeStyle 293 expression medium (Thermo Fisher Scientiﬁc) at 37°C and 8% CO2.
NPC1 constructs. NPC1 domain C sequences (residues 373 to 620) ﬂanked by sequences that form
antiparallel coiled coils as previously described (35) were cloned into the pcDNA3.1() vector. Constructs
made included glycosylation mutants in HsNPC1 domain C (L414ND416T, K498NG500S, and N598A),
while those in DrNPC1 domain C were N414A, N498A, and R600T. DrNPC1 domain C chimeras were made
by substituting these residues for human residues 373 to 475 (chimera 1), 476 to 536 (chimera 2), 537
to 620 (chimera 3), 493 to 502 (chimera 4), 502 to 512 (chimera 5), and 513 to 522 (chimera 6), and the
point mutations made were E502D, Y503F, I505V, H506Y, F509Y, and S511T. The constructs were then
transiently transfected into HEK 293T cells, and the supernatant with secreted protein was harvested after
72 h and used in ELISAs. Puriﬁed proteins were made by transfecting FreeStyle 293-F cells in suspension,
harvesting cells 72 h posttransfection, and purifying them by incubation with His-60 nickel resin. The
proteins were eluted at 500 mM imidazole and pH 7.6 and dialyzed into 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES), 150 mM NaCl, pH 5.5. Domain C chimeras in the full-length NPC1
were generated by seamlessly replacing the domain C sequences in HsNPC1. The constructs were
subcloned into the pBABE-puro retroviral vector and stably transfected into CHO-M12 cells by retroviral
transduction, as previously described (22). All constructs possessed N-terminal Flag tags.
VSV pseudotype infections. Replication-incompetent vesicular stomatitis virus Indiana (VSV) pseu-
dotypes encoding enhanced green ﬂuorescent protein (eGFP) in the ﬁrst position and EBOV GP in place
of VSV G were made as previously described (9, 36). EBOV GPΔMuc matches the EBOV/H.sapiens-tc/
COD/1976/Yambuku-Mayinga isolate amino acid sequence (GenBank accession number AF086833) but
lacks the mucin-like domain (Δ309–489; ΔMuc) (37). Unless otherwise indicated, virus titers were
determined on Vero grivet monkey cells by manual counting of eGFP-positive cells. Cleaved EBOV GP
(GPCL) was generated in vitro using the bacterial protease thermolysin (250 g/ml) (Sigma-Aldrich, St.
Louis, MO) for 1 h at 37°C as described previously (38, 39), and the reaction was stopped by adding the
metalloprotease inhibitor phosphoramidon (1 mM) (Sigma-Aldrich).
Authentic Ebola virus infections. CHO cells, seeded in black Cellcoat 96-well plates (Greiner
Bio-One, North America, Monroe, NC) were incubated with Ebola virus/H.sapiens-tc/COD/1995/Kikwit-
9510621 at the indicated multiplicity of infection in a biosafety level 4 (BSL-4) laboratory located at
USAMRIID. Following a 1-h absorption, virus inoculum was removed and cells were washed once with
phosphate-buffered saline (PBS). Cells were then incubated at 37°C, 5% CO2, and 80% humidity for 72 h,
at which time the cells were washed once with PBS and submerged in 10% formalin prior to removal
from the BSL-4 laboratory. Formalin was removed, and cells were washed 3 times with PBS. Cells were
blocked by adding 3% bovine serum albumin (BSA)-PBS to each well and incubating the cells at 37°C for
2 h. Cells were incubated with EBOV GP-speciﬁc monoclonal antibody (MAb) KZ52, diluted to 1 g/ml
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in 3% BSA-PBS, at room temperature for 2 h. Cells were washed 3 times with PBS prior to addition of goat
anti-human IgG-Alexa Fluor 488 (Thermo Fisher Scientiﬁc) secondary antibody. Following a 1-h incuba-
tion with secondary antibody, cells were washed 3 times prior to addition of Hoechst 33342 (Thermo
Fisher Scientiﬁc) diluted in PBS. Cells were imaged and percentages of virus-infected cells were calculated
using the Operetta high-content imaging system (PerkinElmer, Waltham, MA) and Harmony high-content
imaging and analysis software (PerkinElmer).
GPCL-NPC1 domain C capture ELISA. Normalization of NPC1 domain C supernatants and proteins
was carried out as previously described (25): resolution on SDS-PAGE gels followed by immunoblotting
with anti-Flag primary antibody (Sigma-Aldrich) and anti-mouse Alexa-680 secondary antibody (Thermo
Fisher Scientiﬁc) and quantiﬁcation on the Li-Cor Odyssey imager (Li-Cor Biosciences, Lincoln, NE).
Capture ELISAs were also performed as previously described (22, 25). Brieﬂy, high-binding 96-well ELISA
plates (Corning, Corning, NY) were coated with KZ52 (40) (2 g/ml in PBS) and then blocked using PBS
containing 3% bovine serum albumin (PBSA). Pseudotyped EBOV was cleaved with thermolysin (250 g/
ml) at 37°C for 1 h and captured on the plate. Unbound virus was washed off, and serial dilutions of either
Flag-tagged puriﬁed soluble NPC1 domain C (domain C; 0 to 40 g/ml) or supernatants from transient
transfections of the NPC1 constructs on HEK 293T cells were added. Bound domain C was detected by
a horseradish peroxidase-conjugated anti-Flag antibody and Ultra-TMB substrate (Thermo Fisher). EC50
values were calculated from binding curves generated by nonlinear regression analysis using Prism
(GraphPad Software, La Jolla, CA). Binding ELISAs were done in duplicate and in at least two independent
experiments. All incubation steps were done at 37°C for 1 h or at 4°C overnight.
Immunoﬂuorescence. Imaging was performed in U2OS or CHO cells grown on 12-mm coverslips
and ﬁxed with 4% paraformaldehyde. For antibody staining, the coverslips were incubated with an
anti-Flag antibody (Sigma-Aldrich) in PBS containing 0.1% Triton X-100 and 1% BSA. Detection was by
incubation with Alexa 488-conjugated secondary antibodies (Thermo Fisher Scientiﬁc). For ﬁlipin stain-
ing, the coverslips were stained with 50 g/ml of Streptomyces ﬁlipinensis ﬁlipin III complex (Sigma-
Aldrich) in PBS for 1 h. Coverslips were mounted on glass slides using ProLong antifade reagent (Thermo
Fisher Scientiﬁc), and images were acquired with an inverted ﬂuorescence microscope equipped with a
63 high-numerical-aperture oil objective.
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